Published in Arthritis Res Ther on September 23, 2004
Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc (2009) 1.38
The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther (2008) 1.33
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther (2006) 1.17
Etanercept and venous thromboembolism: a case series. J Med Case Rep (2010) 0.89
Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. J Dtsch Dermatol Ges (2012) 0.89
Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis. Acta Pharmacol Sin (2010) 0.89
A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis. Clin Rheumatol (2006) 0.88
Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol (2008) 0.85
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80
Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab. Arthritis Res Ther (2009) 0.80
Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int (2005) 0.78
Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report. Med Sci Monit (2014) 0.78
Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ (2005) 0.77
Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro. Dig Dis Sci (2012) 0.76
The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis. Clinics (Sao Paulo) (2013) 0.75
Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α. Int Arch Med (2012) 0.75
A De Novo Arisen Case of Primary Adrenal Insufficiency in an Adolescent Patient With Crohn Disease: A Case report. Medicine (Baltimore) (2015) 0.75
Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results. Rheumatol Int (2006) 0.75
Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome. Case Rep Rheumatol (2014) 0.75
Infliximab-induced autoantibodies: a multicenter study. Clin Rheumatol (2015) 0.75
MPO-ANCA-associated necrotizing glomerulonephritis in rheumatoid arthritis; a case report and review of literature. J Nephropathol (2016) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum (1984) 20.51
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 4.68
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology (2001) 2.69
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut (2002) 2.26
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol (2003) 1.68
In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol (2001) 1.59
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology (2003) 1.52
antiphospholipid antibodies and RA: presence of beta2GP1 independent aCL. Ann Rheum Dis (2001) 1.44
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum (2003) 1.41
Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest (2001) 1.40
Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs (2000) 1.30
Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet (2002) 1.30
Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol (2002) 1.29
Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol (1997) 1.28
The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin Immunol Immunopathol (1991) 1.17
Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med (2003) 1.15
Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther (1999) 1.12
Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis (2002) 1.10
Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost (2002) 0.97
Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol (1991) 0.96
The use of laboratory tests in diagnosis and monitoring of systemic lupus erythematosus. J Nephrol (2003) 0.95
Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis (2003) 0.90
Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis. Rheumatology (Oxford) (2000) 0.87
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases. Curr Opin Immunol (2000) 0.84
Revisiting the anticardiolipin test and its standardization. Lupus (2002) 0.83
Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis (2003) 0.82
Prevalence of antiphospholipid antibodies in patients with ankylosing spondylitis. J Rheumatol (1995) 0.81
Complement activation in plasma before and after infliximab treatment in Crohn disease. Scand J Gastroenterol (2003) 0.81
Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome. Clin Chem (2001) 0.79
Hepatitis C virus infection is frequently associated with high titers of anti-thyroid antibodies. Int J Immunopathol Pharmacol (2003) 0.79
Rheumatoid arthritis and fibromyalgia: a frequent unrelated association complicating disease management. J Rheumatol (2009) 4.14
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Retracted Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol (2009) 3.84
Acute-onset chronic inflammatory demyelinating polyneuropathy with cranial nerve involvement, dysautonomia, respiratory failure, and autoantibodies. Muscle Nerve (2010) 2.78
Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum (2013) 2.60
Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med (2006) 2.56
Increased percentage of CD4+CD25+ regulatory T cells during septic shock is due to the decrease of CD4+CD25- lymphocytes. Crit Care Med (2004) 2.51
Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med (2003) 2.32
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2010) 2.22
Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine (2012) 2.20
Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood (2003) 2.16
Methylene blue-treated plasma: an increased allergy risk? J Allergy Clin Immunol (2012) 2.11
Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med (2005) 2.07
T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J Exp Med (2014) 1.82
The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2002) 1.67
Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology (2002) 1.49
Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J Immunol (2006) 1.41
The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett (2004) 1.37
Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol Lett (2006) 1.36
Analytical requirements for measuring monocytic human lymphocyte antigen DR by flow cytometry: application to the monitoring of patients with septic shock. Clin Chem (2002) 1.20
Both percentage of gammadelta T lymphocytes and CD3 expression are reduced during septic shock. Crit Care Med (2005) 1.18
Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood (2002) 1.18
Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin Chem Lab Med (2004) 1.17
Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw (2006) 1.09
Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2007) 1.07
Calcium-sensing receptor autoantibodies are relevant markers of acquired hypoparathyroidism. J Clin Endocrinol Metab (2004) 1.01
Murine dendritic cell transdifferentiation into osteoclasts is differentially regulated by innate and adaptive cytokines. Eur J Immunol (2007) 1.00
Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. Genes Chromosomes Cancer (2007) 0.97
The temporal relationship between the onset of type 1 diabetes and celiac disease: a study based on immunoglobulin a antitransglutaminase screening. Pediatrics (2004) 0.96
Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Arch Immunol Ther Exp (Warsz) (2010) 0.94
Natural killer cells and T cells induce different types of skin reactions during recall responses to haptens. Eur J Immunol (2011) 0.94
Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma. Br J Haematol (2003) 0.93
Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock. Clin Immunol (2005) 0.93
Monitoring of basophil activation using CD63 and CCR3 in allergy to muscle relaxant drugs. Clin Immunol (2002) 0.92
Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatology (Oxford) (2009) 0.90
Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies. Bull Cancer (2004) 0.89
Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis (2005) 0.89
Effects of prostaglandin D(2) and 5-lipoxygenase products on the expression of CD203c and CD11b by basophils. J Pharmacol Exp Ther (2004) 0.88
Evaluation of a point-of-care test based on deamidated gliadin peptides for celiac disease screening in a large pediatric population. Eur J Gastroenterol Hepatol (2012) 0.88
Mapping of IgE-binding epitopes on the major latex allergen Hev b 2 and the cross-reacting 1,3beta-glucanase fruit allergens as a molecular basis for the latex-fruit syndrome. Mol Immunol (2009) 0.87
The collection of NFATc1-dependent transcripts in the osteoclast includes numerous genes non-essential to physiologic bone resorption. Bone (2012) 0.87
Butyrate strongly inhibits in vitro stimulated release of cytokines in blood. Dig Dis Sci (2002) 0.86
Localization of tissue transglutaminase and N (epsilon)-(gamma) -glutamyl lysine in duodenal cucosa during the development of mucosal atrophy in coeliac disease. Virchows Arch (2005) 0.86
Immune responses elicited in tertiary lymphoid tissues display distinctive features. PLoS One (2010) 0.86
The Th2 response as monitored by CRTH2 or CCR3 expression is severely decreased during septic shock. Clin Immunol (2004) 0.84
Calcitonin gene related peptide and N-procalcitonin modulate CD11b upregulation in lipopolysaccharide activated monocytes and neutrophils. Intensive Care Med (2003) 0.84
Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol (2010) 0.83
Tumor necrosis factor-alpha mRNA stability in human peripheral blood cells after lipopolysaccharide stimulation. Eur Cytokine Netw (2002) 0.83
Negativity of the basophil activation test in quinolone hypersensitivity: a breakthrough for provocation test decision-making. Int Arch Allergy Immunol (2011) 0.83
Hyperparathyroidism in a patient with autoimmune polyglandular syndrome. Intern Med (2008) 0.82
Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients. Nutrition (2013) 0.82
Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C. Bull Cancer (2004) 0.82
Safety, efficacy and predictive factors of efficacy of a single intra-articular injection of non-animal-stabilized-hyaluronic-acid in the hip joint: results of a standardized follow-up of patients treated for hip osteoarthritis in daily practice. Arch Orthop Trauma Surg (2008) 0.82
Allergenicity of Hev b 13, a major esterase allergen in natural rubber latex (Hevea brasiliensis) allergy, does not only depend on its carbohydrate moiety. Mol Immunol (2009) 0.81
Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study. PLoS One (2013) 0.81
IgA anti-transglutaminase antibodies as a tool for screening atypical forms of coeliac disease in a French at-risk paediatric population. Eur J Gastroenterol Hepatol (2005) 0.81
High serum procalcitonin levels do not predict bacteremia in adult patients with acute fever. Clin Infect Dis (2003) 0.81
Monitoring NK cell activity in patients with hematological malignancies. Oncoimmunology (2013) 0.81
Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci (2007) 0.81
Carbonic anhydrase III: a new target for autoantibodies in autoimmune diseases. Autoimmunity (2007) 0.80
A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection. Kidney Int (2011) 0.79
Prevalence of anticentromere F protein autoantibodies in 347 patients with non-Hodgkin's lymphoma. Ann N Y Acad Sci (2005) 0.79
Calcium-sensing receptor autoantibodies in primary hyperparathyroidism. Clin Chim Acta (2009) 0.79
Early diagnosis of celiac disease in IgA deficient children: contribution of a point-of-care test. BMC Gastroenterol (2014) 0.79
Autoimmune hypoparathyroidism in a 12-year-old girl with McKusick cartilage hair hypoplasia. Pediatr Nephrol (2009) 0.78
FcgammaRIIIb and complement component C7 codeficiency in a patient with recurrence of fulminant meningococcal septic shock. Clin Infect Dis (2005) 0.78
Clinical significance of anti-histidyl-tRNA synthetase (Jo1) autoantibodies. Ann N Y Acad Sci (2007) 0.77
Improvement in diagnosis of rheumatoid arthritis using dual indirect immunofluorescence and immunoblotting assays for antifilaggrin autoantibodies: a retrospective 3 year study. J Rheumatol (2002) 0.77
Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies). Ann Surg Oncol (2013) 0.77
Enteral immunotherapy in the treatment of chronic enterocolitis in interleukin-10-deficient mice. Hepatogastroenterology (2003) 0.77
Cytokine pattern in cystic fibrosis patients during antibiotic therapy and gene therapy using adenoviral vector. Eur Cytokine Netw (2002) 0.77
Development of miniaturized immunoassay: influence of surface chemistry and comparison with enzyme-linked immunosorbent assay and Western blot. Anal Biochem (2010) 0.77
Celiac disease diagnosis: impact of guidelines on medical prescription in France. J Dig Dis (2014) 0.76
Autoantibodies directed against the UDP-glucuronosyltransferases in human autoimmune hepatitis. Autoimmun Rev (2004) 0.76
Are immunoglobulin A anti-gliadin antibodies helpful in diagnosing coeliac disease in children younger than 2 years? J Pediatr Gastroenterol Nutr (2012) 0.76
A new target for autoantibodies in patients with rheumatoid arthritis. Ann N Y Acad Sci (2007) 0.76
Long-term treatment reduction and steroids withdrawal in children with autoimmune hepatitis: a single centre experience on 55 children. Eur J Gastroenterol Hepatol (2009) 0.75
When to stop in the quest of formes frustes of connective tissue disease? Clin Rheumatol (2007) 0.75
Reply: To PMID 22664163. J Allergy Clin Immunol (2013) 0.75
Induction of high expression of CCR7 and high production of IL-12 in human monocyte-derived dendritic cells by a new bacterial component: LCOS 1013. Int Immunopharmacol (2008) 0.75
[Rheumatoid arthritis: a general disease and local diseases]. Rev Prat (2005) 0.75
The basophil activation test: a sensitive test in the diagnosis of allergic immediate hypersensitivity to pristinamycin. Int Arch Allergy Immunol (2015) 0.75
Spinal cord compression revealing a lambda light chain multiple myeloma. Joint Bone Spine (2013) 0.75
Generation of monocyte-derived dendritic cells in patients with hereditary hemochromatosis. Clin Immunol (2002) 0.75
[Secondary staphylococcus aureus psoas abscess with anti-tumor necrosis factor therapy]. Rev Prat (2015) 0.75
Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma. Arch Immunol Ther Exp (Warsz) (2013) 0.75
Urticarial vasculitis and asymptomatic acquired C1 esterase inhibitor deficiency revealing an angioimmunoblastic T cell lymphoma. Eur J Dermatol (2010) 0.75
[Homeostasis of natural killer cells]. Med Sci (Paris) (2012) 0.75
Allogeneic reaction induces dendritic cell maturation through proinflammatory cytokine secretion. Transplantation (2004) 0.75